At Triumvira Immunologics, Inc., our team is dedicated to a vision of finding a cure and providing new hope for patients with life-threatening disease.
Co-founded in 2015 by licensing technology out of McMaster University and Bloom Burton & Co., Triumvira is working to achieve this vision by developing a proprietary T cell Antigen Coupler (TAC) technology, thought to be safer and more efficacious than current cancer treatments including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies.
We are an emergent US company with operations in the United States and Canada. We bring together talent from a wide range of disciplines including immunobiology, drug development, fundraising, commercialization and finance, with decades of experience across big pharma and small biotech, multiple industries and academia. We are passionate about science that pushes the limits, the patients that drive the heart of our work, and the wellness of our employees. We embrace flexibility. If you are looking for a career where you are encouraged to be innovative, challenge the status quo, and have some fun while doing it, Triumvira is the place for you.
For more information about Triumvira career opportunities, please see our Careers web page at:
https://triumvira.com/contact-us/careers/
Co-founded in 2015 by licensing technology out of McMaster University and Bloom Burton & Co., Triumvira is working to achieve this vision by developing a proprietary T cell Antigen Coupler (TAC) technology, thought to be safer and more efficacious than current cancer treatments including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies.
We are an emergent US company with operations in the United States and Canada. We bring together talent from a wide range of disciplines including immunobiology, drug development, fundraising, commercialization and finance, with decades of experience across big pharma and small biotech, multiple industries and academia. We are passionate about science that pushes the limits, the patients that drive the heart of our work, and the wellness of our employees. We embrace flexibility. If you are looking for a career where you are encouraged to be innovative, challenge the status quo, and have some fun while doing it, Triumvira is the place for you.
For more information about Triumvira career opportunities, please see our Careers web page at:
https://triumvira.com/contact-us/careers/
Location: United States, Texas, Austin
Employees: 11-50
Total raised: $55M
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | Checkmate ... | checkmatec... |
| - | Myeloma In... | myelomainv... |
| - | B Capital ... | b.capital/ |
| 19.03.2022 | B Capital ... | bcapgroup.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.08.2020 | Series A | $55M | - |
Mentions in press and media 15
| Date | Title | Description |
| 03.09.2024 | The Rise of Private Credit: SeaTown's Bold Move in Asia | In the ever-evolving landscape of finance, private credit is emerging as a formidable player. SeaTown Holdings International, a subsidiary of Temasek, has just closed its second private credit fund, SeaTown Private Credit Fund II (PCF II), ... |
| 29.08.2024 | Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms | Results Highlights for Interim Results ended 30 June 2024 Revenue reached RMB981.8 million Gross profit amounted to RMB339.1 million Net profit grew by 956.0 YoY to RMB144.2 million Adjusted non-IFRS net profit reached RMB168.2 million, inc... |
| 21.03.2022 | Climate tech companies in the spotlight as SEC votes on new ESG disclosure proposal | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. All eyes are on the Securities and Exchange Commission, which is expected to vote on a new set of... |
| 21.03.2022 | Triumvira Immunologics Closes Extension of Series A; Brings Total To Approx. $100M | Triumvira Immunologics, an Austin, TX-based clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, completed an extensi... |
| 13.11.2021 | Triumvira Announces Data from Gastric Cancer Preclinical Study to be Presented at SITC Annual Meeting | Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that do not require gene editing and co-opt the natural biology of T cells to treat patients with solid ... |
| 21.09.2021 | Triumvira Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform | Lonza and Triumvira Immunologics ("Triumvira") announced that the first patient has been dosed with Triumvira's investigational T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, in development for the treatme... |
| 26.04.2021 | Triumvira Appoints Teresa McRoberts as Chief Financial Officer and Announces Senior Level Promotions | Triumvira Immunologics (“Triumvira” or the “Company”), a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Teresa McRoberts as Chief Financial ... |
| 30.08.2020 | Triumvira Immunologics raises $55M in Series A funding round for new form of cancer cell therapy | The company’s pipeline consists of four preclinical assets, the most advanced of which are in studies to prepare for an application to start clinical development. The two product candidates – both autologous cell therapies referred to as TA... |
| 27.08.2020 | Triumvira Immunologics Nabs $55M Series A | AUSTIN, TX, Triumvira Immunologics, a biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, has completed a $55 million Series A financing round. >> Click here for more funding data on Tri... |
| 27.08.2020 | Triumvira snags $55M Series A to guide TAC technology to the clinic | Triumvira Immunologics wants to bring its T-cell antigen coupler (TAC) technology to the clinic early next year, and it plans on riding a $55 million Series A to get there. Paul Lammers The Austin, TX-based biotech announce... |
Show more